Liquidia Corp (NASDAQ:LQDA) reported mixed results for the fourth quarter on Thursday.

The company posted quarterly earnings of 15 cents per share which missed the analyst consensus estimate of 17 cents per share. The company reported quarterly sales of $92.021 million which beat the analyst consensus estimate of $83.634 million.

Dr. Roger Jeffs, Liquidia’s Chief Executive Officer, said, “As we close 2025, we are encouraged by how quickly YUTREPIA® has taken hold in clinical practice, placing it among one of the top specialty drug launches over the past five years across all therapeutic categories. Adoption continues to broaden across PAH and PH-ILD, with increasing depth in treatment centers and more experience transitioning appropriate patients from oral, inhaled and systemic prostacyclin therapies.”

Liquidia shares gained 4.5% to trade at $36.08 on Friday.

These analysts made changes to their price targets on Guidewire Software following earnings announcement.

• HC Wainwright & Co. analyst Andrew S. Fein maintained Liquidia with a Buy and raised the price target from $50 to $55.
• Wells Fargo analyst Benjamin Burnett maintained the stock with an Overweight rating and raised the price target from $31 to $44.

Considering buying LQDA stock? Here’s what analysts think:

Photo via Shutterstock